New Treatment Strategies for Inflammatory Bowel Disease using a novel NF-κB inhibitior (DHMEQ)

点击翻译按钮获取中文摘要

A novel NF-κB inhibitor, DHMEQ, strongly ameliorated development of two types of experimental colitis in mice (DSS colitis and TNBS colitis) and DHMEQ appears as a promising candidate for treatment of inflammatory bowel disease. On the otherhand, we explored the development of another stronger NF-κB inhibitor and got3-[(dodecylthiocarbonyl)-methyl]-glutarimide (DTCM-G). We also demonstrated DTCM-G notably attenuated two types of experimental murine models of IBD. We investigated the underlying mechanism in the anti-inflammatory effect of DTCM-G by using RAW264.7 cellsand demonstrated that the inhibition of AKT and GSK-3β activations were related with theanti-inflammatory effect of DTCM-G.